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VASCULAR BIOLOGY
A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing
monocytes, blood “resident” monocytes, and embryonic macrophages suggests
common functions and developmental relationships
*Ferdinando Pucci,1-3 *Mary Anna Venneri,1,2 Daniela Biziato,1,2 Alessandro Nonis,4 Davide Moi,1,2 Antonio Sica,5
Clelia Di Serio,4 †Luigi Naldini,1-3 and †Michele De Palma1,2
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We previously showed that Tie2-expressing
monocytes (TEMs) have nonredundant
proangiogenic activity in tumors. Here, we
compared the gene expression profile of
tumor-infiltrating TEMs with that of tumor-
associated macrophages (TAMs), spleen-
derived Gr1Cd11b neutrophils/myeloid-
derived suppressor cells, circulating
“inflammatory” and “resident” monocytes,
and tumor-derived endothelial cells (ECs)
by quantitative polymerase chain reaction–
based gene arrays. TEMs sharply differed
from ECs and Gr1Cd11b cells but were
highly related to TAMs. Nevertheless, sev-
eral genes were differentially expressed
between TEMs and TAMs, highlighting a
TEM signature consistent with enhanced
proangiogenic/tissue-remodeling activity
and lower proinflammatory activity. We
validated these findings in models of on-
cogenesis and transgenic mice express-
ing a microRNA-regulated Tie2-GFP re-
porter. Remarkably, resident monocytes
and TEMs on one hand, and inflammatory
monocytes and TAMs on the other hand,
expressed coordinated gene expression
profiles, suggesting that the 2 blood
monocyte subsets are committed to dis-
tinct extravascular fates in the tumor mi-
croenvironment. We further showed that
a prominent proportion of embryonic/
fetal macrophages, which participate in
tissue morphogenesis, expressed distin-
guishing TEM genes. It is tempting to
speculate that Tie2 embryonic/fetal mac-
rophages, resident blood monocytes, and
tumor-infiltrating TEMs represent distinct
developmental stages of a TEM lineage
committed to execute physiologic proan-
giogenic and tissue-remodeling pro-
grams, which can be coopted by tumors.
(Blood. 2009;114:901-914)
Introduction
Experimental data suggest that chronic inflammation promotes
tumor development by recruiting innate immune cells.1,2 One
mechanism by which these cells may foster tumor progression is
the promotion of angiogenesis.3,4 Virtually every innate immune
cell type has been implicated in tumor angiogenesis, most notably
mast cells, tumor-associated macrophages (TAMs), Tie2-expressing
monocytes (TEMs), neutrophils, and the so-called “myeloid-
derived suppressor cells” (MDSCs), a heterogeneous population
comprising both immature and differentiated myeloid cells that
expand in tumor-bearing hosts.4-6
Tumors recruit circulating monocytes, which extravasate and differ-
entiate into TAMs. TAMs are thought to produce several growth factors,
cytokines, and extracellular matrix remodeling molecules that together
facilitate tumor angiogenesis, invasion, and metastasis.7 Although it is a
common theme in tumor biology that the fate of tumor-homing
monocytes is modulated directly by the tumor microenvironment,2,7 it is
possible that distinct circulating monocyte subsets may contribute
distinct macrophage subpopulations in tumors. Indeed, circulating
monocytes, as identified by physical properties and Cd115 (Csf1
receptor) expression, can be divided into at least 2 subsets according to
the expression of surface markers. In mice, expression of Gr1, Ccr2 (the
receptor of Ccl2, a potent monocyte chemoattractant), Sell (L-selectin,
or Cd62l), Cx3cr1 (the receptor for the chemokine fractalkine), and
Cd43 distinguishes “inflammatory” (Gr1Ccr2Cd62lCx3cr1lowCd43)
from “resident” (Gr1Ccr2Cd62lCx3cr1highCd43) monocytes.8,9 In-
flammatory monocytes are considered the precursors of macrophages
and dendritic cells (DCs) recruited to inflamed tissues, whereas resident
monocytes patrol blood vessels and perhaps supply certain organs with a
resident population of macrophage-lineage cells.8 Pahler et al10 sug-
gested that TAMs mostly derive from Ccr2 inflammatory monocytes;
indeed, tumors grown in Ccr2 null mice, which have reduced numbers
of circulating inflammatory but not resident monocytes,11 recruit few
TAMs.10 In vivo imaging has recently suggested that TAMs/macro-
phages comprise subsets endowed with different migratory activity12;
whether such heterogeneity of TAM behavior reflects the existence of
developmentally and/or functionally distinct subsets in tumors is cur-
rently unknown. Moreover, the identification of putative monocyte/
macrophage subsets in tumors is currently limited by the paucity of
suitable markers that may distinguish TAM subpopulations.7
TEMs13-17 are a subset of circulating and tumor-infiltrating
monocytes expressing the angiopoietin receptor Tie2.18 Our previ-
ous studies indicated that TEMs are proangiogenic when isolated
from either tumors or peripheral blood, suggesting their commit-
ment to a proangiogenic function already in the circulation.
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Figure 1. Gene expression profile of TEMs, TAMs, MDSCs, PMs, and ECs. (A) Flow cytometry analyses of tumors grown subcutaneously in wild-type FVB mice (n  4) and
made into single-cell suspensions shows that the majority of tumor-infiltrating myeloid cells (gated as Cd11b cells, dot plot on the left) are highly enriched in F4/80 or Cd48
macrophages (dot plots on the right). One representative experiment is shown. (B) Quantitative PCR analysis of TEMs (n  4), TAMs (n  4), and ECs (n  2) showing the
expression level of relevant genes. Results show CT values (mean  SEM) over endogenous control Gapdh. The lower the CT, the higher the expression level. TEMs and
TAMs express Cd45 (pan-hematopoietic–specific marker) and F4/80 (macrophage-specific marker) to similar extent. Vegfr2 (endothelial-specific marker) is expressed robustly
only by ECs. TEMs express Tie2 to a significantly higher extent than TAMs (P  .05). (C) Quantitative PCR-based, multigene array analysis of TEMs (n  3), TAMs (n  3),
and ECs (n  1) showing the expression level (CT vs 2m) of relevant EC (top panel) and hematopoietic/myeloid (bottom panel) genes. TEMs and TAMs robustly express
classic hematopoietic/myeloid genes but not EC genes. (D) Morphology (May-Gru¨nwald-Giemsa staining) of TAMs (top panel) and TEMs (bottom panel) FACS-sorted from
N202 tumors grown for 3 weeks in Tie2-GFP transgenic mice (n  2 independent experiments). Arrows indicate large macrophages containing conspicuous cytoplasmic
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Although mouse TEMs are a minor proportion of the bulk of
tumor-infiltrating macrophages, fluorescence-activated cell sort-
ing (FACS)–isolated, tumor-derived TEMs enhanced angiogen-
esis to a greater extent than TAMs when coinjected with tumor
cells subcutaneously in mice.14 Similarly, human blood–derived
Tie2 monocytes were more proangiogenic than Tie2-negative
monocytes when coinjected with tumor cells subcutaneously in
athymic mice.16 Moreover, the selective elimination of TEMs by
a conditional suicide gene approach inhibited angiogenesis and
tumor growth in several mouse tumor models, suggesting that
TEMs have nonredundant, proangiogenic activity in tumors.14
Although TEMs express Tie2, which has long been regarded as
an endothelial cell (EC)–specific molecule, they are distinct
from endothelial progenitor cells3 (EPCs) and do not incorporate
in the tumor endothelium.13 Yet, little is known of the molecular
identity of TEMs, and their relationship with TAMs, other
tumor-infiltrating myeloid cells, and circulating monocytes
remains to be investigated.
To address these issues, we isolated TEMs, TAMs, and relevant
myeloid cell populations, including circulating monocyte subsets
and splenic Gr1Cd11b neutrophils/MDSCs, and profiled their
gene expression by a quantitative polymerase chain reaction
(PCR)–based multigene array approach. Our data indicate that
tumor-derived TEMs are a subset of TAMs expressing a distinguish-
ing gene signature consistent with proangiogenic and tissue-
remodeling activity. Remarkably, the TEM signature also distin-
guishes resident from inflammatory monocytes in the blood of
tumor-free mice, indicating its association with a specific monocyte
developmental stage or lineage. Moreover, TEM-specific markers
are expressed by a significant proportion of embryonic/fetal
macrophages,19,20 which appear early in development and are found
at sites of angiogenesis and tissue remodeling. Overall, these data
suggest the existence of a TEM lineage of monocytes that play
important roles during organ and tumor development and
vascularization.
Methods
Materials and methods are reported in full as supplemental data (available
on the Blood website; see the Supplemental Materials link at the top of the
online article). A comprehensive list of antibodies used in this study is
presented as supplemental Table 1.
Transgenic mice and lentiviral vector constructs
Briefly, the Tie2-GFPmir142T lentiviral vector (LV) was generated by
cloning 4 tandem copies of a 23-bp sequence with perfect complementarity
to microRNA-142,21 downstream to the wPRE sequence in the Tie2-GFP
LV.13 CD1/Tie2-GFPmir142T transgenic mice were generated by LV-
mediated transgenesis, as described previously,14 and bred for 6 generations
before use. All animal procedures were performed according to protocols
approved by the Animal Care and Use Committee of the Fondazione San
Raffaele del Monte Tabor and communicated to the Ministry of Health and
local authorities according to the Italian law.
Real-time quantitative PCR analysis and statistical analysis
After cell sorting, cells were washed in low-protein buffer and total
mRNA purified following RNeasy Micro/Mini kit guidelines (QIAGEN).
RNA was quantified and retrotranscribed with SuperScript III (Invitro-
gen). To obtain adequate amounts of cDNA for each gene profiling
experiment (interrogating 280 genes), 1 to 3 cell sorting sessions were
required. Quantitative PCR analyses were performed with TaqMan
assays from Applied Biosystems. We used either single-gene TaqMan
assays to analyze the expression of individual genes, or multigene
TaqMan low-density arrays. We used 2 custom-made and one premade
(Immune Panel) TaqMan low-density arrays, each measuring the
expression of 96 genes in 4 technical replicates. A total of 100 ng to 1 g
cDNA was loaded on each array. Quantitative PCR was run for
35 (low-density arrays) or 40 to 45 cycles (individual gene assays) in
standard mode using an ABI7900HT apparatus (Applied Biosystems).
The SDS 2.2.1 software was used to extract raw data. The difference
between the threshold cycle (CT) of each gene and that of the
endogenous controls 2m or Gapdh (CT) was used to determine gene
expression. The lower the CT, the higher the gene expression level.
Statistical methods and other relevant information are described in full
in the supplemental data.
Results
Isolation of TEMs and TAMs from murine tumors
To gene profile TEMs and TAMs, we chose a quantitative PCR
approach because it allows for identifying low-abundance tran-
scripts from small amounts of mRNA. We used low-density
quantitative PCR arrays with standardized fluidics, which ensure
reproducibility, intersample comparison, and global analysis. We
sorted TEMs, TAMs, and ECs from N202 mammary tumors grown
subcutaneously in Tie2-GFP transgenic mice14; in this model, GFP
expression can be conveniently used to discriminate TEMs from
other tumor-infiltrating myeloid cells. However, purification of
tumor-derived TEMs is technically challenging because of their
scarcity and weak GFP expression level. Moreover, both TEMs
and ECs express GFP in Tie2-GFP mice.14 These factors contrib-
ute to increase the risk of contamination from other cell types,
ECs in particular. To address this issue, we first developed a model
to assay the presence of contaminating ECs in our TEM prepara-
tions, and selected a cell sorting formula that enabled the purifi-
cation of EC-free TEM fractions (supplemental data; supplemen-
tal Figure 1).
In N202 tumors, the wide majority of the tumor-infiltrating
Cd11b cells were Emr1/F4/80 and Cd48 (77% 6% and
88% 5%, respectively; mean frequency of marker positive
cells SD; n 4), thus representing myeloid cells highly en-
riched in TAMs (Figure 1A). We then sorted TEMs as Tie2-
GFPCd11bCd31low/, TAMs as Tie2-GFPCd11bCd31low/,
and ECs as Tie2-GFPCd11bCd31 cells (supplemental Figure
2). To validate the sorted cell populations, we measured expres-
sion of the hematopoietic lineage-specific marker Ptprc/Cd45,
the macrophage-specific marker F4/80, the EC-specific marker
Vegfr2 (Flk1), and Tie2/Tek, in TEMs, TAMs, and ECs (n  2-4
biologic samples) by quantitative PCR (Figure 1B). Both TEMs
and TAMs expressed high-level Cd45 and F4/80, which con-
firmed their hematopoietic origin and monocyte/macrophage
identity. Of note, Tie2 expression was significantly higher in
TEMs than in TAMs (t test: P  .05; n  4).
phagosomes. Scale bar represents 30 m. Photos are representative of n  25 photos/sample. (E) One-dot-one-gene representation of the expression profile (280 genes
analyzed) of tumor-derived TEMs (n  3), TAMs (n  3), and ECs (n  1), Gr1Cd11b neutrophils/MDSCs (n  2; isolated from the spleen of tumor bearing mice) and PMs
(n  2), analyzed by quantitative PCR as in panel C. Each one-dot-one-gene plot compares 2 cell types, as indicated. The data show that TEMs are highly related to TAMs
(Pearson linear correlation: 0.926) but sharply differ from Gr1Cd11b cells (0.682), PMs (0.701), and ECs (0.240).
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We then analyzed the clonogenic potential of TEMs and TAMs
in colony-forming cell assays. Sorted TEMs did not generate
hematopoietic colonies (supplemental Table 2), indicating that they
are virtually devoid of hematopoietic progenitors.
Tumor TEMs are monocytes/macrophages expressing a
distinguishing gene signature
To investigate the nature of TEMs, we measured the expression of
280 genes (supplemental Table 3) previously implicated in angio-
genesis, tissue remodeling, immune response, cell adhesion, chemo-
taxis, neural guidance, vascular morphogenesis, in TEMs (n 3
independent experiments), TAMs (n 3), and ECs (n  1). We
extended the gene expression analysis to peritoneal macrophages
(PMs; sorted as Cd11bF4/80Cd31low/ cells; n 2) and neutro-
phils/MDSCs isolated from the spleen of N202 tumor-bearing mice
(sorted as Cd11bGr1 cells; n 2).
The expression profile of TEMs clearly indicated that they
belong to the monocyte/macrophage lineage and are distinct from
ECs. Indeed, TEMs robustly express typical “myeloid genes,” but
low to negligible amounts of “EC genes” (Figure 1C). A list of the
genes highly expressed in TEMs and grouped by function is shown
in supplemental Table 4. Among the highly expressed monocyte/
macrophage genes were Csf1 receptor (Csf1r/Cd115), Fc receptors
(Fcgr1, Fcgr2b, Fcgr3), fractalkine receptor (Cx3cr1), macrosialin
(Cd68), F4/80, Cd14, scavenger receptors (mannose receptor
Mrc1, macrophage scavenger receptors Msr1 and Msr2, hemoglobin/
haptoglobin scavenger receptor Cd163, membrane-bound scaven-
ger receptor/cytokine Cxcl16), endopeptidases (metalloproteases,
cathepsins), and several integrins. In addition, TEMs express
monocyte/macrophage-derived cytokines (Il1a, Il1b, Il6, Tnf,
Tgfb1), chemokines (Ccl4, Ccl3/Mip1a/b, Cxcl10, Cxcl9, Cxcl11),
and classic proangiogenic factors (Vegfa, Vegfb, Sema4d, Pdgfb,
lactadherin [Mfge8], thymidine phosphorylase [Ecgf1], placen-
tal growth factor [Pgf]).
Morphologic analysis of FACS-sorted cells (n 2 independent
experiments; Figure 1D) showed that TEMs are a homogeneous
Table 1. Genes differentially expressed between tumor-derived TEMs and TAMs
Gene Fold more Fold less Ct P Gene Fold more Fold less Ct P
Up-regulated
Cd163 15.8 6.3  .001 Timp2 2.8 4.5  .01
Lyve1 14.1 6.1  .001 Plxnd1 2.8 6.2  .01
Igf1 8.2 9.3  .001 Efna1 2.7 12.6  .01
Stab1 6.4 5.5  .001 Slamf1 2.6 14.6  .05
Mrc1 5.3 3.0  .001 Fcgr3 2.6 3.1  .05
Sema6d 5.2 15.2  .001 Angpt1 2.6 14.2  .05
Nrp1 4.6 6.3  .001 Sema3c 2.6 12.3  .05
Cxcl12 4.4 10.6  .001 Timp3 2.5 12.2  .05
Thbs3 4.3 12.1  .001 Kit 2.5 14.9  .05
Cxcl13 4.3 5.1  .001 Sdc2 2.5 9.1  .05
Efnb2 4.2 12.9  .01 Efnb1 2.5 12.0  .05
Neo1 4.1 15.1  .01 Cdh5 2.4 11.6  .05
Plxna3 4.1 12.8  .001 Plxnb2 2.4 6.3  .05
Itga2 4.0 16.3  .05 Il4ra 2.3 5.1  .05
Plxna1 3.6 8.1  .001 Il10ra 2.2 6.5  .05
Msr2 3.5 4.4  .001 Arg1 2.2 5.7  .05
Tlr4 3.5 7.8  .01 Hpse 2.1 5.6  .05
Plxna4 3.1 10.9  .01 Serpinb2 2.1 9.8  .05
Edg1 3.0 8.1  .01 Itgb1 2.1 5.0  .05
Fcgr2b 2.9 3.9  .01
Down-regulated
Il1b 6.6 2.4  .001 Ptprc 2.7 3.7  .01
Ptgs2 5.0 5.5  .001 Ctss 2.7 0.8  .01
Il4 4.0 12.0  .001 Tgfb1 2.6 4.2  .05
Nos2 3.9 8.8  .001 Il18 2.6 8.2  .05
Ccr7 3.8 7.6  .001 Sell 2.5 10.3  .05
Il12a 3.6 16.2  .01 Ccr2 2.5 5.8  .05
Smad7 3.6 8.2  .001 Il12b 2.5 11.8  .05
Bcl2l1 3.2 6.6  .01 Nfkb2 2.5 5.9  .05
Stat4 3.1 10.7  .01 Fas 2.4 9.8  .05
Tnf 3.1 4.0  .01 Gusb 2.4 4.9  .05
Il13 3.1 12.8  .01 Smad3 2.4 9.0  .05
Actb 3.0 1.0  .01 Socs1 2.4 6.6  .05
Edn1 3.0 11.0  .01 Bax 2.4 6.2  .05
Ccl5 3.0 4.3  .01 Pgk1 2.4 4.1  .05
H2-Ea 3.0 5.1  .01 Ski 2.3 6.1  .05
Vegfa 2.9 4.5  .01 Csf1 2.3 7.8  .05
Il1a 2.9 5.2  .01 Ctla4 2.2 12.9  .05
Cxcl10 2.8 2.9  .01 Stat1 2.1 3.7  .05
Cd80 2.8 9.1  .01 Tnfrsf18 2.1 12.0  .05
Ece1 2.7 13.1  .05 Tbx21 2.1 12.1  .05
Cxcl11 2.7 6.6  .01
The expression level of each gene in tumor-derived TEMs is indicated as fold-change versus TAMs. The Ct of each gene was calculated using 2m as endogenous
control.
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cell population with typical monocyte/macrophage morphology
( 94% of the cells with bean-shaped nucleus and large cyto-
plasm). On the other hand, TAMs displayed a greater extent of
morphologic heterogeneity and contained both monocyte-like cells
and large macrophages with features of activated phagocytes
(rounded nucleus; large cytoplasm with numerous vacuoles). The
cell morphology corroborated the gene expression data that both
TEMs and TAMs belong to the monocyte/macrophage lineage.
A comparison between the gene expression profile of TEMs and
TAMs revealed that the 2 monocyte/macrophage subsets were
highly related (Figure 1E). However, TEMs differed significantly
from spleen-derived Gr1Cd11b neutrophils/MDSCs, PMs, and
tumor-derived ECs. To rigorously identify differences between
TEMs and TAMs, we implemented in R (http://www.R-project.
org) a multivariate regression model, similarly to the model
implemented in sas,22 to compute over the whole dataset and
estimate the fold change in gene expression for each single target
gene. This model jointly evaluates the role of different variables of
interest providing for (1) statistical significance of the observed
differences in expression level across the whole set of experimental
samples, (2) identifying the experimental variables that contribute
to each individual measurement, and (3) subtracting experimen-
tally introduced biases to obtain a stringent estimate of the actual
biologic differences. Statistical analysis of the data revealed several
differentially expressed genes between TEMs and TAMs (29% at
P  .05; Table 1). Among these, Arginase1 (Arg1) and several
scavenger receptors23 (Cd163, stabilin-1 [Stab1], Mrc1, Msr2)
were up-regulated, whereas Nos2, proinflammatory24 and antian-
giogenic25 molecules (Il1b, Ptgs2/Cox2, Il12a, Tnf, Ccl5, Cxcl10,
Cxcl11) were down-regulated in TEMs versus TAMs. With
reference to the M1-M2 polarization paradigm proposed by
some authors,23 the enhanced expression of scavenger receptors
and the down-regulation of inflammatory mediators by TEMs
would place them at the M2 extreme of the polarization window
(ie, TEMs are significantly more M2-skewed than TAMs),
consistent with their marked proangiogenic and protumoral
activity.14,15 Among the most differentially expressed genes
were also the hyaluronan receptor-1 (Lyve1), neuropilin-1 (Nrp1),
stromal cell derived factor-1 (Cxcl12/Sdf-1), insulin growth
factor-1 (Igf1), and Toll-like receptor-4 (Tlr4), all of which were
up-regulated in TEMs. The finding of several differentially ex-
pressed genes strongly suggests that TEMs represent a distinct
subset or differentiation state of TAMs.
We then validated the gene expression results by protein
analysis, either by immunofluorescence staining (IFS) and confocal
microscopy of tumor sections (Figure 2) or by flow cytometry of
tumor-derived cell suspensions (Figure 3). We used 2 different
tumor models: N202 tumors grown subcutaneously in Tie2-GFP
transgenic mice14 (n  5 for IFS; n 3-7 for flow cytometry); and
mammary tumors spontaneously arising in MMTV-PyMT trans-
genic mice26 previously transplanted with Tie2-GFP bone marrow
(BM) cells (n 4 tumors from 4 mice for IFS), as described.27
Whereas in Tie2-GFP mice both TEMs and ECs express GFP
(Figure 2A), in BM-transplanted mice only TEMs are GFP
Figure 2. Confocal immunofluorescence analysis of mouse tumors identifies a distinguishing TEM signature. (A) N202 mammary tumors (n  5) grown
subcutaneously in Tie2-GFP transgenic mice and analyzed for GFP (green) and Cd68 (red) expression. Confocal planes are shown individually and after merging (merge). The
left panels show GFP blood vessels and abundant Cd68 macrophages; scale bar represents 120 m. High-magnification photos (right panels) show perivascular
Tie2-GFPCd68 TEMs (arrows); scale bar represents 60 m. For each tumor, at least 3 sections were analyzed. (B) Mammary tumors spontaneously arising in MMTV-PyMT
transgenic mice (n  4) previously transplanted with Tie2-GFP BM cells and analyzed for GFP (green), Lyve1 or Mrc1 (red), and F4/80 (blue) expression. Abundant F4/80
macrophages are evenly distributed within the tumor mass, whereas GFPLyve1 or GFPMrc1 TEMs cells are mainly found in stromal septa surrounding tumor cell nests.
Virtually all the Tie2-GFP cells express Lyve1 and Mrc1. Note that some of the Tie2-GFP Lyve1 or Mrc1 cells may represent host-derived, nontransgenic TEMs. Scale bar
represents 60 m. For each tumor, at least 10 sections were analyzed for each marker.
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(Figure 2B, supplemental Figure 3). GFPF4/80 TEMs were
frequently located in stromal tumor areas, whereas GFPF4/80
TAMs were evenly distributed throughout the tumor mass (Figure
2B). IFS and/or flow analyses showed differential expression of
Lyve1, Mrc1, Tlr4, interleukin-4 receptor-alpha (Il4ra), Cd163, and
Stab1 but not of F4/80, Tlr2, Itga4 (Cd49d), and Cd86, between
TEMs and TAMs, in agreement with the RNA data (Figures 2B,
3A, supplemental Figure 3). Although the Itgax (Cd11c) mRNA
was expressed similarly in TEMs and TAMs (Table 1), TEMs were
Cd11clow/ and TAMs markedly Cd11c by flow cytometry and
IFS (Figure 3B; and data not shown). TEMs were c-kit and did not
express Fc	R1, Ly6G, Ly6C, and Cd41, which are mast cell-,
neutrophil-, inflammatory monocyte-, and megakaryocyte/platelet-
specific markers, respectively (Figure 3B). Together with the
mRNA data, these results identify a unique TEM surface marker
profile, which distinguishes them from the bulk of TAMs and
related myeloid-lineage cells.
TEMs are refractory to proinflammatory stimuli
The gene expression data indicated that TEMs have a Th2/M2
phenotype. We wondered whether Th1 stimulation could modulate
this phenotype. To this aim, we stimulated (or left unstimulated)
tumor-derived TEMs, TAMs, and PMs with either Th1 (LPS Ifng)
or Th2 (Il4) cytokines (n 3 independent experiments) and
evaluated the expression of established responder genes6,23 (Nos2
and Il12a for Th1 responses; Arg1 and Ccl17 for Th2 responses).
Th1 stimulation elicited minor responses in TEMs and TAMs,
compared with PMs (Figure 4). Conversely, TEMs and TAMs were
more responsive than PMs to Th2 stimulation. These results
Figure 3. Flow cytometric analysis of tumors identifies a distinguishing TEM signature. (A) Flow analysis of some of the genes that were either differentially expressed or
not differentially expressed between TEMs and TAMs. N202 mammary tumors grown subcutaneously in Tie2-GFP transgenic were made into single-cell suspensions and
TEMs and TAMs gated as Tie2-GFPCd11b7AAD and Tie2-GFPCd11b7AAD cells, respectively. In agreement with the mRNA data, TEMs but not TAMs robustly and
uniformly express Tlr4, Mrc1, Il4ra, and Cd163 (left panels). Genes not differentially expressed by quantitative PCR are similarly expressed by TEMs and TAMs (right panels).
For each marker, at least 3 independent analyses were performed; for each analysis, at least 3 tumors were pooled together and made into single-cell suspensions. (B) Further
phenotypic characterization of TEMs and TAMs. Note that TEMs do not express c-kit or granulocyte (Ly6G), inflammatory monocyte (Ly6C), DC (Cd11c), mast cell (Fc	RI), and
megakaryocyte/platelet (Cd41) markers. For each marker, at least 3 independent analyses were performed.
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indicated that both tumor-derived TEMs and TAMs display
defective Th1 responses but can respond to Th2 stimuli. Of note,
both unstimulated and Th2-stimulated TEMs had higher Arg1
and lower Nos2 expression than TAMs, in agreement with the
gene profile data.
Circulating TEMs belong to the resident monocyte subset
We then analyzed the circulating TEMs, which may be the
precursors of tumor TEMs.14 We previously speculated that circu-
lating TEMs belong to the myeloid lineage based on their
expression of Cd11b and CD14 in mice and humans, respec-
tively.14,16 However, several cell surface–associated markers are
coexpressed by endothelial- and hematopoietic-lineage cells.5 To
rigorously demonstrate that TEMs belong to the hematopoietic
lineage, we used a genetic approach. MicroRNAs (miR) regulate
networks of gene expression and help determining cell identity and
lineage specification. miR-142 is specifically expressed in the
hematopoietic lineage28; we previously showed that expression of a
GFP reporter gene containing miR-142 target sequences was
suppressed specifically in all hematopoietic-lineage cells of trans-
genic mice,21 indicating stringent association of miR-142 expres-
sion with hematopoietic cell specification. Here, we incorporated
miR-142 target sequences (miR142T) downstream to the Tie2-GFP
reporter and generated Tie2-GFPmiR142T transgenic mice by
LV-mediated transgenesis. In the progeny of these mice, GFP was
efficiently expressed in Cd31 ECs (Figure 5A) but, as opposed to
mice carrying the unmodified transgene, it was completely sup-
pressed in circulating monocytes (n 3; Figure 5B). These results
indicate robust miR-142 activity in circulating TEMs, providing
genetic evidence for their hematopoietic lineage and further
clarifying that they are distinct from circulating ECs. In agreement
with these findings, the majority of circulating GFP cells in
Tie2-GFP mice expressed the monocyte-specific marker Csf1r/
Cd115 (84% 5%, mean SD; n 16; Figure 5C). Of note, only
30% plus or minus 6% (n 13) of the total Cd115 monocytes
were GFP, indicating that TEMs represent a subset of circulating
monocytes (Figure 5D). The GFP TEMs were mostly Gr1
(84% 5%, n 10), Cd62l (74%  6%, n 7), and Cd43
(80% 6%, n 10), thus expressing a resident monocyte marker
profile (Figure 5F).
Common gene signature of circulating resident monocytes and
tumor-infiltrating TEMs
We then analyzed gene expression (39 genes of interest, selected
among those analyzed in tumor-derived cells) in Cd115Gr1
resident and Cd115Gr1 inflammatory monocytes obtained from
the blood of tumor-free mice (n 4 independent experiments), and
compared the results with those obtained with tumor-derived TEMs
and TAMs (Table 2). Remarkably, 22 of 39 genes displayed
concordant expression in resident versus inflammatory monocytes
and TEMs versus TAMs (exact binomial test; P  .003). These
included Arg1, Igf1, Cxcl12, Lyve1, Stab1, Cd163, Edg1, Mrc1
(up-regulated in resident monocytes and TEMs vs inflammatory
monocytes and TAMs, respectively), and Sell, Ccr2, Ptgs2/Cox2
(down-regulated). Only one gene, Il12a, displayed discordant
expression, whereas the remainder genes were differentially ex-
pressed in either resident versus inflammatory monocytes or TEMs
versus TAMs. The association of the TEM gene expression
signature, which enriches for tissue-remodeling versus proinflam-
matory genes, with resident monocytes suggests that resident and
inflammatory blood monocytes represent 2 functionally distinct
subsets that may be differentially committed to generate tumor-
infiltrating TEMs and TAMs, respectively.
A prominent macrophage population expresses typical TEM
genes in developing embryos
The physiologic role of TEMs is unknown. We investigated the
presence and distribution of TEMs during embryonic/fetal develop-
ment and analyzed embryos of Tie2-GFP transgenic mice14 from
E7.5 to E15.5 (n 1-4 litters/stage) by IFS and confocal micros-
copy. Starting from E8.5 and throughout embryonic development,
GFP was consistently expressed in Cd31 ECs forming vascular
structures and in scattered hematopoietic cells expressing Cd45,
Cd11b, or F4/80 (Figure 6A-B; and data not shown). Anti-Tie2
immunostaining confirmed expression of the Tie2 receptor by the
GFP cells (supplemental Figure 5A). The GFPCd45 or GFPF4/
Figure 4. TEMs, like TAMs, are refractory to proinflammatory stimuli. In vitro stimulation of PMs, TEMs, and TAMs with Th1 (LPS  Ifng) and Th2 (Il4) cytokines, or the
same cells left unstimulated (Ctrl). Top and bottom panels show the expression of Th1 (Nos2, Il12a) and Th2 (Arg1, Ccl17) responder genes, respectively. The expression of
each gene is indicated as fold change (mean  2 
 SD of 3 independent experiments) over its expression in unstimulated PMs (for PMs) or unstimulated TAMs (for TEMs and
TAMs); endogenous control: 2m. Note that TEMs and TAMs are much less responsive than PMs to Th1 cytokine treatment. Conversely, Th2 cytokine stimulation elicits a
greater response in TEMs and TAMs than in PMs.
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80 cells were particularly abundant in the mesenchyme surround-
ing the developing neural organs, between somites and in interdigi-
tal zones, but were hardly found in the fetal liver, a major
hematopoietic organ (Figure 6A-C; and data not shown). In several
instances, GFPF4/80 cells were found intermixed with develop-
ing blood vessels, eg, in the meninges, mesencephalic flexure of the
brain, and hyaloid cavity of the eye. A large proportion of the
embryonic/fetal Cd11b or F4/80 cells (such as those of the fetal
liver) did not express GFP (supplemental Figure 5B-C). Of note,
the GFP (or Tie2) F4/80 cells expressed typical TEM markers,
including Mrc1 (Figure 6C), Cd163, and Lyve1 (supplemental
Figure 5D-E, Figure 7C).
We then performed flow cytometry on embryos from E8.5 to
E15.5 (n 1 or 2 samples/stage, by pooling  8 embryos/stage).
As expected, the GFP cells, which comprise both ECs and F4/80
macrophages, uniformly expressed the Tie2 receptor (Figure 7A).
Whereas only 10% plus or minus 5% of the total myeloid-lineage
cells (as stained by Cd11b) expressed GFP (n 5 at different
stages), a greater proportion of the F4/80 cells were GFP
(27% 4%; n  7). Several F4/80 macrophages coexpressed
Lyve1 (Figure 7B); the F4/80Lyve1 cells, which were mostly
excluded from the fetal liver, were virtually all GFP (Figure 7B).
We confirmed these findings by IFS of wild-type embryos (n 3 at
E8.5, E10.5, and E13.5), which showed colocalization of Lyve1
Figure 5. Circulating TEMs are bona fide hematopoietic cells distinct from circulating ECs and express a resident monocyte phenotype. (A) Analysis of mouse liver
by IFS (left) and flow cytometry (right). (Left panels) Expression of GFP (green) in Cd31 (red) liver sinusoids of Tie2-GFPmir142T mice (n  2). Scale bar represents 60 m.
Dot plots on the right show liver tissue–derived single-cell suspensions of representative wild-type (n  1), Tie2-GFP (n  2), and Tie2-GFPmir142T (n  3) mice. Note that
GFP is expressed robustly in the Cd31 ECs of both Tie2-GFPmir142T and Tie2-GFP mice. (B) Flow cytometry analysis of blood cells of representative wild-type (n  1),
Tie2-GFP (n  2), and Tie2-GFPmir142T (n  3) mice. Cd11b myeloid cells are gated (dot plot on the left) and GFP expression analyzed in this hematopoietic subset (dot
plots on the right). Note that GFP is expressed in the Cd11b SSClow monocytes of Tie2-GFP, but not Tie2-GFPmir142T mice. Ly indicates lymphocytes; Gr, granulocytes; Mo,
monocytes. (C-E) Flow cytometry analysis of the blood of Tie2-GFP transgenic mice. (C) Virtually all the Tie2-GFP TEMs (green gate in the dot plot on the left; n  16) are
Cd11bCd1157AAD monocytes (dot plot on the right). (D) Only a fraction ( 30%; n  13) of the Cd11bCd1157AAD monocytes (dot plot on the left) are Tie2-GFP (dot
plot in the middle). Monocytes from wild-type mice (n  5) were used to set the gate for GFP-positive events (dot plot on the right). (E) Dot plots show the expression of surface
markers that can distinguish resident from inflammatory monocytes (n  7-10). The Cd115GFP7AAD cells were gated and the expression of Cd43, Gr1, and L-selectin
(Cd62l) analyzed. The majority of Tie2-GFPCd1157AAD TEMs are Cd43Gr1Cd62l resident monocytes. Representative experiments are shown.
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Figure 6. Characterization of mouse embryonic/fetal macrophages. (A) A representative E13.5 Tie2-GFP transgenic embryo analyzed for GFP (green), Cd45 (red), and
Cd31 (blue) expression. The dorsal area of the embryo is shown. GFP is uniformly expressed by Cd31 blood vessels and by scattered Tie2-GFPCd45Cd31 hematopoietic
cells (arrows). Note that several Cd45Cd31 hematopoietic cells are GFP (arrowheads). Scale bar represents 60 m. Similar results were obtained in E8.5 to E15.5
embryos. Results are representative of n  8 litters (each including 2 or 3 embryos) analyzed. For each embryo, at least 3 sections were analyzed. (B) A representative E14.5
Tie2-GFP transgenic embryo analyzed for GFP (green), Cd31 (red), and F4/80 (blue) expression. The brain of the embryo is shown. GFP is uniformly expressed by Cd31
blood vessels and by scattered Tie2-GFPF4/80Cd31 macrophages (arrows). Note that several F4/80Cd31 macrophages are GFP (arrowheads). Scale bar represents
60 m. Embryos were analyzed as described in panel A. (C) A representative E12.5 Tie2-GFP transgenic embryo analyzed for GFP (green), Mrc1 (red), and F4/80 (blue)
expression. The spinal cord of the embryo is shown. GFP is expressed by Mrc1F4/80 macrophages that are intermixed with GFPMrc1F4/80 blood vessels in the
meninges (inset). Scale bar represents 60 m. The 2 bottom panels show a high-power magnification of the inset shown above. Note the perivascular GFPMrc1F4/80
macrophages. Embryos were analyzed as described in panel A.
Table 2. Genes expressed either differentially or not between resident and inflammatory monocytes
Up-regulated Down-regulated
Fold more Ct P Fold less Ct P
Arg1 58.7 11.5  .001 Chi3l3/Ym1 18.0 6.4  .001
Cxcl12 20.5 15.1  .001 Sell 9.5 8.1  .001
Lyve1 14.7 12.8  .001 Ccr2 5.6 7.6  .001
Stab1 14.1 16.7  .001 Ptgs2 4.5 18.1  .001
Igf1 13.6 15.3  .001 Not differentially expressed
Cd163 5.2 13.3  .001 Angpt1 Cx3cr1 Itga4 Tbx21
Edg1 4.7 9.0  .001 Angpt2 Egf Il4 Tgfb1
Il10 4.4 16.0  .001 Ccr7 Fgf2 Vegfr2 Tlr4
Mmp9 3.1 12.3  .05 Csf1R Vegfr1 Mmp12 Tnf
Mrc1 2.7 9.9  .05 Cd80 Ifng Nos2 Tnfrsf18
Il12a 2.6 14.0  .05 Cd86 Il1b Nrp1
Mmp2 2.5 17.6  .05
Bold text indicates concordant expression in resident versus inflammatory monocytes and TEMs versus TAMs. Text without bold or underlining indicates significantly
up-regulated/down-regulated either in resident versus inflammatory monocytes or TEMs versus TAMs. Underlined text indicates discordant expression in resident versus
inflammatory monocytes and TEMs versus TAMs.
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Figure 7. A distinguishing TEM signature expressed by mouse embryonic/fetal macrophages. (A) Flow cytometry analysis of representative E14.5 Tie2-GFP transgenic
embryos ( 8 embryos pooled together). Virtually all GFP cells express the Tie2 receptor. Whereas a small proportion of the Cd11b cells are GFP, a substantial proportion
of the F4/80 cells are GFP. The Cd11b or F4/80, GFP cells mostly represent ECs. Similar results were obtained in E8.5 to E14.5 embryos. Results are representative of
n  11 litters analyzed. (B) Flow cytometric analysis of representative E12.5 Tie2-GFP transgenic embryos ( 8 embryos pooled together), analyzed as whole embryos (total
cells), or embryos without fetal liver (total cells without fetal liver), or fetal liver alone (fetal liver). In whole embryos, the majority of Lyve1 cells are F4/80 macrophages. In
embryos without fetal liver, virtually all the Lyve1 cells are F4/80 macrophages. In the fetal liver, the majority of the Lyve1 cells are F4/80 cells, probably representing
lymphatic ECs. The Lyve1F4/80 macrophages (green gate in the dot plot at bottom left) display enhanced GFP expression (histogram at bottom right, open green line)
compared with the Lyve1 cells (red gate and filled red line). (C) A representative E12.5 wild-type embryo analyzed for Lyve1 (green), Tie2 receptor (red), and F4/80 (blue)
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and Tie2 receptor by a fraction of the F4/80 macrophages
(Figure 7C).
The early time of appearance, morphology, and distribution of
the GFPF4/80 cells within the embryo were consistent with
those of embryonic/fetal macrophages.19,29,30 FACS sorting (after
pooling 8 E13.5 embryos depleted of the fetal liver) and morpho-
logic analysis (Figure 7D) showed that the embryonic/fetal
GFPCd11b cells were a homogeneous population of large
phagocytes ( 95% macrophages with rounded nucleus, large
cytoplasm filled with phagosomes and vacuoles). Flow cytometry
indicated that the GFPF4/80 macrophages did not express the
hematopoietic progenitor markers c-kit and Sca-1 (n 2 samples
analyzed at E13.5 and E14.5; supplemental Figure 6), corroborat-
ing the notion that they represent mature macrophages. FACS-
sorted GFPCd11b cells were also highly enriched in macro-
phages ( 80%) but contained a measurable fraction of immature
myeloid elements.
We did not detect GFP macrophages in Tie2-GFPmiR142T
embryos by IFS (Figure 7E); of note, these embryos showed
uniform and robust vascular GFP marking. In agreement with the
IFS data, flow cytometry analyses showed that the Cd11b or
F4/80 myeloid cells of Tie2-GFPmiR142T embryos were uni-
formly GFP (Figure 7F), whereas the Cd11bGFP (or F4/
80GFP) ECs from either Tie2-GFPmiR142T or Tie2-GFP
transgenic mice displayed similar GFP mean fluorescence activity.
These data indicate robust activity of miR-142 in embryonic/fetal
Tie2F4/80 cells, further confirming that they represent bona fide
hematopoietic-lineage cells.
Finally, we analyzed gene expression (25 selected genes,
selected among those analyzed in tumor-derived cells) in
GFPCd11b and GFPCd11b macrophages obtained from E13.5
Tie2-GFP transgenic embryos (n 2 independent experiments,
each by pooling 15 E13.5 embryos depleted of the fetal liver) and
compared the results with those obtained with tumor-derived TEMs
and TAMs (Table 3). Fourteen of 25 genes displayed concordant
expression in GFP versus GFP embryonic/fetal macrophages
and tumor-derived TEMs versus TAMs (exact binomial test;
P  .02). These included Igf1, Lyve1, Arg1, Mrc1, Cd163, and
Stab1 (up-regulated in GFP embryonic/fetal macrophages and
TEMs versus GFP embryonic/fetal macrophages and TAMs,
respectively) and Sell (down-regulated). Remarkably, when we
extended the analysis to include gene expression data obtained
from circulating monocytes (Table 2), 12 of 24 analyzed genes
were found to be coordinately expressed in GFP embryonic/fetal
macrophages, resident monocytes, and tumor-derived TEMs versus
GFP embryonic/fetal macrophages, inflammatory monocytes, and
TAMs (exact binomial test; P  .001).
Discussion
Our gene expression data demonstrate that TEMs are distinct from
endothelial-lineage cells and represent a subset of tumor-
infiltrating macrophages expressing a distinguishing gene signa-
ture, which is consistent with enhanced proangiogenic and tissue-
remodeling activity and lower proinflammatory activity. The “TEM
gene signature” also distinguishes resident from inflammatory
monocytes in the peripheral blood and identifies a population of
embryonic/fetal macrophages that appear early during mouse
development (starting from E8.5) and are preferentially associated
with areas of active tissue remodeling and angiogenesis.
Several studies have reported that mononuclear cells expressing
a reporter gene from Tie2 transcription regulatory elements are
recruited to tumors and ischemic tissues.13,15,31-34 Based on the
assumption that Tie2 expression is specific of ECs, these Tie2
cells were often interpreted as EPCs, even if they expressed
hematopoietic/myeloid markers33 and were often found outside of
the vessel wall.31,33 By implementing stringent combinations of
gene marking and imaging approaches, we previously showed that
these Tie2 mononuclear cells indeed represent myeloid cells.14,15
Here, we conclusively demonstrate that Tie2-expressing cells
recruited to tumors do not belong to the EC lineage and are bona
fide monocytes/macrophages. By comparing tumor-derived TEMs,
TAMs, and ECs, we show that the gene expression profile of TEMs
expression. The dorsal area of the embryo is shown. Note the Lyve1Tie2F4/80 macrophages scattered among Tie2Lyve1F4/80 blood vessels. Scale bar represents
60 m. Results are representative of n  2 litters (each including 3 embryos) analyzed. For each embryo, at least 3 sections were analyzed. (D) Morphology
(May-Gru¨nwald-Giemsa staining) of Tie2-GFPCd11b (left) and Tie2-GFPCd11b (right) cells sorted from E13.5 Tie2-GFP transgenic embryos depleted of the fetal liver.
Scale bar represents 30 m. Photos are representative of n  25 photos/sample. (E) A representative E12.5 Tie2-GFPmir142T transgenic embryo analyzed for GFP (green)
and Mrc1 (red) expression. The spinal cord of the embryo is shown. Note that the Mrc1 macrophages do not express GFP in this mouse model, whereas ECs do. The bottom
right panel shows a high-power magnification of the inset indicated in the bottom left panel. Similar results were obtained in all analyzed embryos (E12.5-E15.5). Results are
representative of n  4 litters (each including 3 embryos) analyzed. For each embryo, at least 3 sections were analyzed. (F) Flow cytometric analysis of representative E12.5
Tie2-GFP and Tie2-GFPmir142T transgenic embryos ( 8 embryos pooled together). Note that in Tie2-GFPmit142T embryos (n  8 litters analyzed at different stages) there
are no Cd11b or F4/80 cells expressing GFP.
Table 3. Genes expressed either differentially or not between Tie2-GFP and Tie2-GFP, Cd11b embryonic/fetal macrophages
Up-regulated Down-regulated
Fold more Ct P Fold less Ct P
Mmp12 39.3 2.3  .001 Sell 35.1 8.8  .001
Igf1 25.0 7.4  .001 Chi3l3/Ym1 15.2 6.1  .001
Lyve1 21.0 3.7  .001 Mmp9 8.3 6.6  .001
Arg1 11.6 4.9  .001 Egf 7.3 12.3  .01
Mrc1 7.2 2.6  .01 Angpt1 4.4 11.5  .05
Cd163 6.4 7.0  .01 Not differentially expressed
Stab1 3.7 1.0  .05 Angpt2 Edg1 Il12a Nrp1
Cx3cr1 3.5 1.0  .05 Csf1r Fgf2 Vegfr2 Tfrc
Cxcl12 Vegfr1 Mmp2 Tlr4
Bold text indicates concordant expression in embryo TEMs versus embryonic macrophages and tumor TEMs versus TAMs. Text without bold or underlining indicates
significantly up-regulated/down-regulated either in embryo TEMs versus embryonic macrophages or tumor TEMs versus TAMs. Underlined text indicates discordant
expression in embryo TEMs versus embryonic macrophages and tumor TEMs versus TAMs.
GENE EXPRESSION SIGNATURE OF TEMs AND TAMs 911BLOOD, 23 JULY 2009  VOLUME 114, NUMBER 4  For personal use only.2012. 
 at ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE on June 12,bloodjournal.hematologylibrary.orgFrom 
is similar to that of TAMs but clearly distinct from that of ECs.
Further data support the non-EC nature of TEMs. Indeed, TEMs
(1) robustly express hematopoietic-specific markers (eg, Cd45,
F4/80, and miR-142, the latter shown using a microRNA-regulated
reporter transgenic mouse line), (2) express low to negligible levels
of EC-specific genes (eg, Vegfr2 and VE-cadherin/Cdh5), and
(3) do not incorporate in the tumor endothelium and often reside in
perivascular spaces. These findings strongly support the notion that
Tie2-expressing cells repeatedly observed in tumors13-15,27,34,35 are
not EPCs. Whether true EPCs contribute to tumor angiogenesis is
still a matter of debate, with recent reports showing a contribution
limited to selected experimental conditions, such as tumors treated
by vascular-disrupting agents or chemotherapy.5,13,36,37
Although TEMs do not physically incorporate in the tumor
endothelium, they seem required for tumor angiogenesis.15 Within
the panel of interrogated genes, many genes previously implicated
in tumor angiogenesis were among the most differentially ex-
pressed between TEMs and TAMs. One such gene is Lyve1
(14-fold up), which encodes for the hyaluronan receptor-1 ex-
pressed on lymphatic ECs and subsets of macrophages. Because
TEMs also express Stab1 (stabilin-1, a hyaluronan receptor;
6.4-fold up) and Cd163 (hemoglobin/haptoglobin scavenger recep-
tor; 15.8-fold up), it is probable that the previously described
Lyve1Stab1Cd163 macrophages observed in tumors, wounds,
and remodeling adipose tissue38,39 indeed represent TEMs. Tlr4, a
Toll-like receptor implicated in tumorigenesis,40 is also preferen-
tially expressed by TEMs (3.5-fold up). Whereas Lyve1 binds
hyaluronic acid (HA), Tlr4 binds to its low-molecular-weight
fragmentation products. The preferential expression of Lyve1,
Stab1, and Tlr4 by TEMs among tumor macrophages suggests a
role of TEM-HA interactions in tumor angiogenesis. Indeed, HA
fragments stimulate MMP production, cell migration, and angiogen-
esis in tumors,41 and up-regulate Irak-M expression by monocytes,
deactivating them and down-regulating their expression of the
antiangiogenic molecules Tnfa and Il12a.42 Interestingly, Tlr4
expression by macrophages has been found to mediate remodeling
of the lung microenvironment and favor subsequent colonization
by tumor cells.43 The expression of Nrp1 (Neuropilin-1, a Vegf
coreceptor; 4.6-fold up) by TEMs might enhance angiogenesis by
clustering Vegf in contact with Vegfr2 ECs, as previously
described.44 Efnb2 (Ephrin-B2; 4.2-fold up) encodes for a transmem-
brane ligand of Ephrin receptors expressed on ECs; the bidirec-
tional signaling between ephrin-B2 and Ephrin receptors modulates
angiogenesis and the development of arteries and veins.45 Sema-
phorin 6D (Sema6d; 5.2-fold up), a transmembrane protein that
binds to membrane-bound plexinB1, may also have proangiogenic
activity in tumors, as it activates Vegfr2-mediated signal transduc-
tion.46 The enhanced expression of Nrp1, Efnb2, and Sema6d by
TEMs may suggest activation of ECs by cell-to-cell contacts.
Another gene up-regulated in TEMs is Cxcl12 (4.4-fold up),
encoding for the stromal cell–derived factor-1 (Sdf1); Cxcl12
released by TEMs may promote angiogenesis by attracting Cxcr4
ECs and other proangiogenic cells in the tumor microenviron-
ment.47 Angpt1 (angiopoietin-1, a Tie2 ligand; 2.6-fold up) ex-
pressed by TEMs may also promote tumor angiogenesis, as
Angpt1-expressing hematopoietic cells stimulate EC sprouting in
embryonic tissues.44 TEMs display up-regulated expression of
Edg1 (sphingosine-1-phosphate receptor; 3.0-fold up). Edg1
null embryos are hemorrhagic and die in utero, a phenotype
associated with impaired vascular maturation and defective recruit-
ment of perivascular cells to angiogenic blood vessels.48 Moreover,
sphingosine-1-phosphate induces macrophages to acquire an anti-
inflammatory phenotype49 (high Arg1, low Nos2 activity). Vegfa,
which is among the most expressed genes in TEMs, was however
down-regulated in TEMs versus TAMs (2.9-fold down), suggesting
that TEMs are exposed to a less hypoxic microenvironment in
tumors, consistent with their preferential localization in peritu-
moral areas and their exclusion from necrotic regions. Interest-
ingly, the ELR-negative CXC chemokines Cxcl10 and Cxcl11 were
down-regulated in TEMs versus TAMs (2.8- and 2.7-fold down,
respectively). These chemokines are transcribed on Irf3/Stat1
activation and are potent inhibitors of angiogenesis.25,50 Overall,
the enhanced expression of several proangiogenic molecules by
TEMs, together with the down-regulation of potent antiangioge-
neic mediators (also including Il12a, 3.6-fold down; Il12b, 2.5-fold
down; Tnfa, 3.1-fold down), may account for their nonredundant
proangiogenic activity in tumors.15
Both mouse and human monocytes can be grouped into
functional subsets.8,9,51-53 We found that circulating TEMs belong
to the Gr1Cd62lCd43 resident monocyte subset. In addition to
our previous data showing that TEMs are proangiogenic,14,15 a
recent report indicated that resident monocytes promote tissue
angiogenesis in the postischemic myocardium.54 Together, these
data may suggest a developmental and functional relationship
between circulating resident monocytes and tumor-infiltrating
TEMs. Our new findings further show that resident monocytes
isolated from the blood of tumor-free mice and tumor-derived
TEMs display a coordinated expression profile, which points to a
commitment of TEM phenotype/function in the peripheral blood.
Arg1, Cxcl12, Lyve1, Igf1, Stab1, Cd163, Mrc1, and Edg1, all
significantly up-regulated in tumor-derived TEMs versus TAMs,
were markedly up-regulated in resident versus inflammatory mono-
cytes. Expression of Il12a (an antiangiogenic molecule) was
down-regulated in TEMs versus TAMs but unexpectedly up-
regulated in resident versus inflammatory monocytes. However,
2 recent reports have shown that both mouse resident and human
blood monocytes rapidly down-regulate Il12 expression on their
extravasation in vivo53 or when exposed in vitro to experimental
conditions mimicking the hypoxic tumor microenvironment.17 The
coordinated expression profiles of resident monocytes/TEMs and
inflammatory monocytes/TAMs suggest that monocyte heterogene-
ity in the peripheral blood may reflect the existence of precursor
populations that are committed to distinct, nonredundant functions
in tumors and growing/regenerating tissues. Yet, the developmental
relationship between the 2 main monocyte subsets remains to be
clarified. It has been proposed that resident monocytes derive from
Gr1 inflammatory monocytes,11,55 implying that the 2 phenotypes
may represent distinct developmental stages along the monocyte
lineage. Further studies will clarify whether TEMs represent a
distinct resident monocyte subpopulation.
Although it has been predicted that TAMs comprise distinct
functional subsets,7 very little is known of the actual functional
heterogeneity of TAMs in tumors. Live imaging analysis12 of
monocyte/macrophage subpopulations expressing the newly identi-
fied cell-surface markers (eg, Mrc1, Lyve1, Tlr4) may better clarify
macrophage heterogeneity and dynamics in tumors. It has been
established that tumors induce macrophages to acquire an immuno-
suppressive function.23 Moreover, tumor-derived factors promote
the expansion of MDSCs, a heterogeneous myeloid population that
can suppress T-cell function,6 in BM, blood, and lymphoid organs.
Inhibition of effective antitumor T cell–dependent immunity by
TAMs and MDSCs may occur in several ways, including produc-
tion of indoleamine dioxygenase and nitric oxide, inhibition of DC
maturation, and attraction of T regulatory cells to the tumor site.6
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Interestingly, among the down-regulated genes in TEMs versus
TAMs were Ccr7 (3.8-fold down), Cd80 (2.8-fold down), Tbx21
(T-box 21 transcription factor; 2.1-fold down), and H2-Ea (class II
major histocompatibility complex, antigen E alpha; 3.0-fold down),
which are all expressed by antigen-presenting cells. Conversely,
Il4ra, which encodes for the type I interleukin-4 receptor previ-
ously shown to be expressed by immunosuppressive MDSCs,56
was up-regulated in TEMs (2.3-fold up). Because tumor TEMs do
not express Cd11c and express low levels of mature antigen-
presenting cell markers (compared with TAMs), it can be envisaged
that they represent deactivated or immature cells. Together, our
findings suggest that TEMs have little ability, if any, to commence
immune responses in tumors, and may well represent an innate
immunosuppressive cell type.
Both mRNA and protein expression data indicated that a
substantial fraction of the F4/80 embryonic/fetal macrophages
express a TEM phenotype (Tie2Lyve1Mrc1Cd163). This
finding points to a functional similarity between embryonic/fetal
macrophages, which have unique developmental and biologic
features among phagocytes,19,20,29 and adult proangiogenic TEMs.
Whereas TEMs represent a minor proportion of the tumor-
infiltrating F4/80 cells and are mostly restricted to viable,
angiogenic tumor areas,15 TEM-like cells appear to be a major
macrophage subset in embryos. Of note, Ojalvo et al recently
reported that the gene expression profile of TAMs significantly
overlaps with enriched transcripts in fetal macrophages.30 By
further narrowing down the gene expression analysis to tumor-,
blood-, and embryo-derived monocyte/macrophage subpopula-
tions (ie, by comparing the Tie2(GFP) with Tie2(GFP)
fraction of each subpopulation), we identified stringent concor-
dance in gene expression/regulation among the Tie2 myeloid
subpopulations analyzed. The identification of “embryonic/fetal
TEMs” extends their role to a physiologic process characterized
by dramatic rates of cell turnover, tissue morphogenesis, and
remodeling, which occur in the absence of exogenous inflamma-
tory stimuli. mRNA data indicated that Tie2-GFP embryonic/
fetal macrophages display greatly enhanced expression of
Mmp12 (metalloelastase; 39-fold up vs GFP counterpart),
suggesting the importance of this protease in physiologic tissue
remodeling57 by embryonic/fetal TEMs.
It is tempting to speculate that TEMs play primary functions in
developing tissues, where they might execute proangiogenic and
proinvasive programs that are coopted by tumors.15 Taken together,
our findings suggest that TEMs represent a circulating reservoir of
monocytes actively recruited to extravascular tissues by noninflam-
matory signals produced not only by tumors, but also by develop-
ing or regenerating tissues. Future studies will be devoted to the
identification of the signals that govern the lineage determination
of TEMs and their recruitment to sites of active tissue
morphogenesis.
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